Strumento inattivo

Altre lingue Ventrus Biosciences Inc Nasdaq

Azioni

US9228221019

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

18/06	Assembly Biosciences, Inc. Dosa il primo partecipante allo studio clinico di Fase 1B che valuta la capsidica di prossima generazione	CI
05/06	Assembly Biosciences presenta nuovi dati che evidenziano l'inibitore dell'ingresso del virus dell'epatite D Abi-6250 al Congresso Easl 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection	18/06
Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid	18/06
Assembly Biosciences Announces $12.6 Million in Equity Financings	17/06
Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.	17/06
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366	10/06
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024	05/06
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024	05/06
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024	22/05
Assembly Biosciences: Q1 Earnings Snapshot	09/05
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights	08/05
Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights	28/03
Assembly Biosciences Announces Effective Date of Reverse Stock Split	08/02
Assembly Biosciences Announces Effective Date of Reverse Stock Split	08/02
Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	19/01
Assembly Biosciences, Inc. Provides Anticipated Development Milestones for 2024	04/01
Assembly Biosciences Provides Anticipated Development Milestones for 2024	04/01
Assembly Biosciences Provides Anticipated Development Milestones for 2024	04/01
Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board	07/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ventrus Biosciences Inc Nasdaq

Azioni

US9228221019

Altre lingue

Filtri